Metabolites of synthetic cannabinoids (SCs) are widely used as markers for identifying SCs’ intake. Polydrug use involving SCs and ethanol may generate new metabolites, namely SC ethyl esters, hereby shown for the first time as new blood markers of SC-alcohol concomitant abuse. We report a case involving both the presence of 5F-PB22 and ethanol and the detection of their transesterifcation product, namely 5F-PB22 ethyl ester, in a postmortem blood sample. This marker was found retrospectively in a preserved femoral blood analyzed via liquid chromatography–high-resolution mass spectrometry. A single-point calibration was used to estimate the concentration of 5F-PB22-Et in the sample, which found to be 0.4 μg/L. Retention time and fragment ions (within ±1 mmu extraction window) of 5F-PB22-Et in the sample gave a remarkable match with a synthetic reference material. To the best of our knowledge, this is the first case report of an SC ethyl ester in a biological sample to indicate SCs and ethanol co-consumption.

中文翻译：

---

在死后血液毒理学分析中检测到的第一例合成大麻酯乙基酯的报道。

合成大麻素（SCs）的代谢物被广泛用作识别SCs摄入量的标记物。涉及SC和乙醇的多药用途可能会产生新的代谢产物，即SC乙酯，因此首次显示为SC酒精伴随滥用的新血液标记。我们报告了一例涉及死后血液样本中5F-PB22和乙醇的存在及其酯交换产物（即5F-PB22乙酯）的检测。该标记物是通过液相色谱-高分辨率质谱分析法在保留的股血中回顾性发现的。单点校准用于估计样品中5F-PB22-Et的浓度，发现浓度为0.4μg/ L。样品中5F-PB22-Et的保留时间和碎片离子（在±1 mmu提取窗口内）与合成参考物质具有显着匹配。据我们所知，这是生物样品中SC乙酯的第一个病例报告，表明SC和乙醇共同消耗。